MALIGNANT MELANOMA

This study tested a new drug (SAR444245) combined with an immunotherapy (cemiplimab) for people with advanced melanoma or squamous cell skin cancer that could not be removed by surgery. The goal was to see if the combination could shrink tumors. The trial was stopped early, and r…

This early-phase study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations. The goal was to check safety, find the right dose, and see if it shrinks tumor…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or delay cancer growth. The trial was ter…

This early-stage study tested a new drug, PF-08046037, alone or with another drug (sasanlimab) in people with advanced lung, head and neck, skin, or pancreatic cancers. The goal was to check safety and how the body processes the drug. Only 8 people took part before the study was …

This early-phase study tested a new drug called PF-07284890, alone or with another drug (binimetinib), in people with advanced solid tumors that have a specific BRAF V600 mutation, including those with brain tumors. The main goals were to check safety, how the drug moves through …

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or no longer responded to standard treatments. The main goal was to check the drug's safety and side effects. The study was terminated early, so r…